Nexavar (sorafenib) — Medica
Renal cell carcinoma (advanced or relapsed)
Initial criteria
- age ≥ 18 years
- relapsed or advanced disease
- clear cell histology
- has tried at least one systemic therapy (e.g., Inlyta, Votrient, Sutent, Cabometyx)
Approval duration
1 year